

## DAFTAR PUSTAKA

- Abebe F, Belay M, Legesse M, K.L.M.C F, Ottenhoff THM. 2018. IgA and IgG against *Mycobacterium tuberculosis* Rv2031 discriminate between pulmonary tuberculosis patients, *Mycobacterium tuberculosis*-infected and non-infected individuals. *Plos One*. vol. 13. no. 1. pp. e0190989.
- Achkar JM, Chan J, Casadevall A. 2015. B cells and antibodies in the defense against *Mycobacterium tuberculosis* infection. *Immunological Reviews*. vol. 264. pp. 167-181.
- Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, Honda S, Prevots DR. 2017. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. *Emerging Infectious Diseases*. vol. 23. no. 3. pp. 439-447.
- Ahmad F, Zubair S, Gupta P, Gupta UD, Patel R, Owais M. 2017. Evaluation of aggregated Ag85B antigen for its biophysical properties, immunogenicity, and vaccination potential in a murine model of tuberculosis infection. *Frontiers in Immunology*. vol. 8. pp. 1608.
- Applied Biosystems. 2009. *DNA sequencing by capillary electrophoresis applied biosystems chemistry guide second edition*. Applied Biosystems. US. diakses 18 April 2016. [https://www3.appliedbiosystems.com/cms/groups/mcb\\_support/documents/generaldocuments/cms\\_041003.pdf](https://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_041003.pdf).
- Aston SJ, Ho A, Jary H, Huwa J, Mitchell T, Ibitoye S, Greenwood S, Joekes E, Daire A, Mallewa J, Everett D, Nyirenda M, Faragher B, Mwandumba HC, Heyderman RS, Gordon SB. 2019. Aetiology and risk factors for mortality in an adult community-acquired pneumonia cohort in Malawi. *American Journal of Respiratory and Critical Care Medicine*. doi: 10.1164/rccm.201807-1333OC. (In Press).
- Babaki MKZ, Soleimanpour S, Rezaee SA. 2017. Antigen 85 complex as a powerful *Mycobacterium tuberculosis* immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. *Microbial Pathogenesis*. vol. 112. pp. 20-29.
- Beamer GL, Cyktor J, Flaherty DK, Stromberg PC, Bridget C, Turner J. 2012. *Mycobacterium tuberculosis* infected CBA/J mice can generate robust and protective responses to antigen Ag85 when delivered as a soluble protein, but fail

- to respond efficiently in the context of natural infection. *European Journal of Immunology*. vol. 42. no. 4. pp. 870-879.
- Belay M, Legesse M, Mihret A, Ottenhoff THM, Franken KL, Bjune G, Abebe F. 2016. IFN-g and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: results of a longitudinal study from an endemic setting. *Journal of Infection*. vol. 72. pp. 189-200.
- Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. 1997. Role of the major antigen of *Mycobacterium tuberculosis* in cell wall biogenesis. *Science*. vol. 276. pp. 1420-1422.
- Berkowitz N, Okorie A, Goliath R, Levitt N, Wilkinson RJ, Oni T. 2018. The prevalence and determinants of active tuberculosis among diabetes patients in Cape Town, South Africa, a high HIV/TB burden setting. *Diabetes Research and Clinical Practice*. vol. 138. pp. 16-25.
- Bhunja SK, Sarkar M, Banerjee A, Giri B. 2015. An update on pathogenesis and management of tuberculosis with special reference to drug resistant. *Asian Pacific Journal of Tropical Disease*. vol. 5. no. 9. pp. 673-686.
- Biofeng. 2013. *pET-SUMO*. Biofeng. China. diakses 4 Mei 2018. <http://www.biofeng.com/zaiti/dachang/pET-SUMO.html>
- Brown TA. 2010. *Gene cloning and DNA analysis an introduction sixth edition*. John Wiley & Sons Ltd. UK.
- Brown TA. 2016. *Gene cloning and DNA analysis an introduction seventh edition*. John Wiley & Sons Ltd. UK.
- Burmester È and Pezzutto A. 2003. *Color atlas of immunology*. Thieme. New York.
- Carroll KC, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, Mitchell TG, McKerrow JH, Sakanari JA. 2016. *Jawetz, melnick & adelberg's medical microbiology 27<sup>th</sup> edition*. McGraw-Hill Companies Inc. USA.
- Cerqueira-Rodrigues B, Mendes A, Correia-Neves M, Nobrega C. 2018. Ag85-focused T-cell immune response controls *Mycobacterium avium* chronic infection. *Plos one*. vol. 13. no. 3. pp. e0193596.
- Chakraborty A, Shivananjaiah AJ, Ramaswamy S, Chikkavenkatappa N. 2018. Chest X ray score (Timika score): an useful adjunct to predict treatment outcome in tuberculosis. *Advances in Respiratory Medicine*. vol. 86. no. 5. pp. 205-210.

- Chen JM, Pojer F, Blasco B, Cole ST. 2010. Towards anti-virulence drugs targeting *esx-1* mediated pathogenesis of *Mycobacterium tuberculosis*, *Drug Discovery Today: Disease Mechanisms*. vol. 7. no. 1. pp. 25-31.
- Cheng J, Wang L, Zhang H, Xia Y. 2015. Diagnostic value of symptom screening for pulmonary tuberculosis in China. *Plos One*. vol. 10. no. 5. pp. e0127725.
- Chien JY, Lai CC, Sheng WH, Yu CJ, Hsueh PR. 2014. Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000–2012. *Emerging Infectious Diseases*. vol. 20. no. 8. pp. 1382–1385.
- Chingonzoh R, Manesen MR, Madlavu MJ, Sopiseka N, Nokwe M, Emwerem M, Musekiwa A, Kuonza LR. 2018. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013. *Plos One*. vol. 13. no. 8. pp. e0202469.
- Chuchottaworn C, Thanachartwet V, Sangsayunh P, Than TZM, Sahassananda D, Surabotsophon M, Desakorn V. 2015. Risk factors for multidrug-resistant tuberculosis among patients with pulmonary tuberculosis at the central chest institute of Thailand. *Plos One*. vol. 10. no. 10. pp. e0139986.
- Coico R and Sunshine G. 2015. *Immunology: a short course*. John Wiley & Sons. West Sussex
- Collins CH, Lyne PM, Grange JM, Falkinham III JO. 2004. *Collins and Lyne's microbiological methods eighth edition*. Arnold. London.
- Coppola M, Arroyo L, van Meijgaarden KE, Franken KL, Geluk A, Barrera LF, Ottenhoff THM. 2017. Differences in IgG responses against infection phase related *Mycobacterium tuberculosis* (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. *Tuberculosis*. vol. 106. pp. 25-32.
- Da Silva PEA and Palomino JC. 2011. Molecular basis and mechanisms of drug resistance in *Mycobacterium tuberculosis*: classical and new drugs. *Journal of Antimicrobial Chemotherapy*. vol. 66. pp. 1417-1430.
- Davila J, Zhang L, Marrs CF, Durmaz R, Yang Z. 2010. Assessment of the genetic diversity of *Mycobacterium tuberculosis* *esxA*, *esxH*, and *fbpB* genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4. *Journal of Biomedicine and Biotechnology*. vol. 2010. pp. 208371.

- de Araujo LS, da Silva N deBM, Leung JAM, Mello FCQ, Saad MHF. 2018. IgG subclasses' response to a set of mycobacterial antigens in different stages of *Mycobacterium tuberculosis* infection. *Tuberculosis*. vol. 108. pp. 70-76.
- Dembic Z. 2015. *The cytokines of the immune system the role of cytokines in disease related to immune response*. Elsevier. United States.
- Demir Y and Beydemir S. 2015. Purification, refolding, and characterization of recombinant human paraoxonase-1. *Turkish Journal of Chemistry*. vol. 39. pp. 764-776.
- Dewi DNSS, Soedarsono, Mertaniasih NM. 2018. T cell epitopes of the *esxA* full gene of *Mycobacterium tuberculosis* from sputum of MDR-TB patients. *African Journal of Infectious Diseases*. vol. 12. no. 2. pp. 66-70.
- Diaclone. 2018. Instruction for use human IL-7 ELISA set. Diaclone. France. diakses 4 Februari 2019. <https://www.diaclone.com/>
- Dieffenbach CW, Lowe TMJ, Dveksler GS. 1993. General concepts for pcr primer design. *Genome Research*. vol. 3. pp. 30-37.
- Dinas Kesehatan Jawa Timur. 2017. *Profil kesehatan Provinsi Jawa Timur tahun 2016*. Dinas Kesehatan Provinsi Jawa Timur. Surabaya. diakses 4 November 2018. [http://www.depkes.go.id/resources/download/profil/PROFIL\\_KES\\_PROVINSI\\_2016/15\\_Jatim\\_2016.pdf](http://www.depkes.go.id/resources/download/profil/PROFIL_KES_PROVINSI_2016/15_Jatim_2016.pdf).
- Dinas Kesehatan Kota Surabaya. 2017. *Profil kesehatan Kota Surabaya tahun 2016*. Dinas Kesehatan Kota Surabaya. Surabaya. diakses 4 November 2018. [http://www.depkes.go.id/resources/download/profil/PROFIL\\_KAB\\_KOTA\\_2016/3578\\_Jatim\\_Kota\\_Surabaya\\_2016.pdf](http://www.depkes.go.id/resources/download/profil/PROFIL_KAB_KOTA_2016/3578_Jatim_Kota_Surabaya_2016.pdf).
- Dotulong JFJ, Sapulete MR, Kandou GD. 2015. Hubungan faktor risiko umur, jenis kelamin dan kepadatan hunian dengan kejadian penyakit TB paru di Desa Wori Kecamatan Wori. *Jurnal Kedokteran Komunitas dan Tropik*. vol. III. no. 2. pp. 57-65.
- Enos M, Sitienei J, Ong'ang'o J, Mungai B, Kamene M, Wambugu J, Kipruto H, Manduku V, Mburu J, Nyaboke D, Ngari F, Omesa E, Omale N, Mwirigi N, Okallo G, Njoroge J, Githiomi M, Mwangi M, Kirathe D, Kiplimo R, Ndombi A, Odeny L, Mailu E, Kandie T, Maina M, Kasera K, Mulama B, Mugi B, Weyenga H. 2018. Kenya tuberculosis prevalence survey 2016: challenges and opportunities of ending TB in Kenya. *Plos One*. vol. 13. no. 12. pp. e0209098.
- Falkinham JO. 1996. Epidemiology of infection by nontuberculous mycobacteria. *Clinical Microbiology Reviews*. vol. 9. no. 2. pp. 177-215.

- Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI. 2008. Type 2 diabetes and multi-drug resistant tuberculosis. *Scandinavian Journal of Infectious Disease*. vol. 40. no. 11-12. pp. 888-893.
- Forrellad MA, Klepp LI, Gioffré A, García JSy, Morbidoni HR, Santangelo MdIP, Cataldi AA, Bigi F. 2013. Virulence factors of the *Mycobacterium tuberculosis* complex. *Virulence*. vol. 4. no. 1. pp. 3-66.
- Franca LTC, Carrilho E, Kist TBL. 2002. A review of DNA sequencing techniques. *Quarterly Reviews of Biophysics*. vol. 35. no. 2. pp. 169-200.
- Fujita Y, Doi Takeshi, Maekura R, Ito M, Yano I. 2006. Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to *Mycobacterium tuberculosis* and *Mycobacterium avium* complex. *Journal of Medical Microbiology*. vol. 55. pp. 189-199.
- Garibyan L and Avashia N. 2013. Polymerase chain reaction. *Journal of Investigative Dermatology*. vol. 133. pp. 1-4.
- Gan SD and Patel KR. 2013. Enzyme immunoassay and enzyme-linked immunosorbent assay. *Journal of Investigative Dermatology*. vol. 133. pp. e12
- Gao J, Zhao L, Wan YY, Zhu B. 2015. Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy. *International Journal of Molecular Sciences*. vol 16. no. 5. pp. 10267-10280.
- Garrity GM, Bell JA, Lilburn TG. 2004. *Taxonomic outline of the prokaryotes bergey's manual of systematic bacteriology second edition*. Springer New York Inc. New York.
- Gennaro ML, Affouf M, Kanaujia GV, Brusasca PN, Mangaura B, Reichman L. 2007. Antibody markers of incident tuberculosis among HIV-infected adults in the USA: a historical prospective study. *International Journal of Tuberculosis and Lung Disease*. vol. 11. no. 6. pp. 624-631.
- Gersh JK, Feldman Z, Greenberger E, Chandra A, Friedman HM, Ho-Foster A, Haas MK. 2018. Tuberculosis among individuals with community-acquired pneumonia presenting to emergency in Gaborone, Botswana. *Journal of Public Health in Africa*. vol. 9. no. 1. pp. 803.
- Ghazawi FM, Faller EM, Sugden SM, Kakal JA, MacPherson PA. 2013. IL-7 downregulates IL-7R $\alpha$  expression in human CD8 T cells by two independent mechanisms. *Immunology and Cell Biology*. vol. 91. no. 2. pp. 149-158.

- Green DA, Whittier S, Greendyke W, Win C, Chen X, Hamele-Bena D. 2016. Outbreak of rapidly growing Nontuberculous Mycobacteria among patients undergoing cosmetic surgery in the Dominican Republic. *Annals of Plastic Surgery*. vol. 78. no. 1. pp. 17-21.
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *American Journal of Respiratory and Critical Care Medicine*. vol. 175. no. 4. pp. 367-416.
- Griffith DE. 2019. *Nontuberculous mycobacterial disease, a comprehensive approach to diagnosis and management*. Springer Nature Switzerland AG. Switzerland.
- Guinn KM, Hickey MJ, Mathur SK, Zakel KL, Grotzke JE, Lewinsohn DM, Smith S, Sherman DR. 2004. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of *Mycobacterium tuberculosis*. *Molecular Microbiology*. vol. 51. no. 2. pp. 359-370.
- Gumilar G, Supriyanti FMT, Siti HH. 2008. *Bioteknologi modul*. FPMIPA Universitas Pendidikan Indonesia. Bandung.
- Gupta RS, Lo B, Son J. 2018. Phylogenomics and comparative genomic studies robustly support division of the genus *Mycobacterium* into an emended genus *Mycobacterium* and four novel genera. *Frontiers in Microbiology*. vol. 9. pp. 67.
- Hafez SA, Elhefnawy AM, Hatata EA, El Ganady AA, Ibrahiem MI. 2013. Detection of extensively drug resistant pulmonary tuberculosis. *Egyptian Journal of Chest Diseases and Tuberculosis*. vol. 62. no. 4. pp. 635-646.
- Hasan NA, Epperson LE, Lawsin A, Rodger RR, Perkins KM, Halpin AL, Perry KA, Moulton-Meissner H, Diekema DJ, Crist MB, Perz JF, Salfinger M, Daley CL, Strong M. 2019. Genomic analysis of cardiac surgery-associated *Mycobacterium chimaera* Infections, United States. *Emerging Infectious Diseases*. vol. 25. no. 3. pp. 559-563.
- Hatano S, Tamura T, Umemura M, Matsuzaki G, Ohara N, Yoshikai Y. 2016. Recombinant *Mycobacterium bovis* bacillus Calmette–Guérin expressing Ag85B-IL-7 fusion protein enhances IL-17A-producing innate  $\gamma\delta$  T cells. *Vaccine*. vol. 34. no. 22. pp. 2490-2495
- Hemmati M, Seghatoleslam A, Rasti M, Ebadat S, Mosavari N, Habibagahi M, Taheri M, Sardarian AR, Mostafavi-Pour Z. 2011. Expression and purification of recombinant *Mycobacterium tuberculosis* (TB) antigens, ESAT-6, CFP-10 and

- ESAT- 6/CFP-10 and their diagnosis potential for detection of TB Patients. *Iran Red Crescent Medical Journal*. vol. 13. no. 8. pp. 556–563.
- Hertz D and Schneider B. 2018. Sex differences in tuberculosis. *Seminars in Immunopathology*. vol. 41. no. 2. pp. 225-237.
- Hiza H, Fenner L, Hela J, Kuchaka D, Sasamalo M, Blauenfeldt T, Kibiki G, Kavishe RA, Mhimbira F, Ruhwald M. 2018. Boosting effect of IL-7 in interferon gamma release assays to diagnose *Mycobacterium tuberculosis* infection. *PLoS One*. vol. 13. no. 8. pp. e0202525.
- Holmberg V, Soini H, Kivelä P, Ollgren J, Ristola M. 2019. Epidemiology and outcome of HIV patients in Finland co-infected with tuberculosis 1998–2015. *BMC Infectious Diseases*. vol. 19. pp. 264.
- Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. 2016. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. *Plos Medicine*. vol. 13. no. 9. pp. e1002119.
- Howe C. 2007. *Gene cloning and manipulation*. Cambridge University Press. New York.
- Huang T, Wu K, Yuan X, Shao S, Wang WY, Wei S. 2016. Molecular analysis of the immunoglobulin genes in goose. *Developmental and Comparative Immunology*. vol. 60. pp. 160-166.
- Huang H, Wang F, Yang E, Wang H, Gao P, Shen H. 2018. Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice. *Experimental and Therapeutic Medicine*. vol. 15. no. 3. pp. 3034-3039.
- Hutchison III CA. 2007. DNA sequencing: bench to bedside and beyond. *Nucleic Acid Research*. vol. 35. no. 18. pp. 6227-6237.
- Idexx. 2013. *ELISA technical guide*. IDEXX Laboratories Inc. USA. diakses 20 Desember 2017. <https://www.idexx.eu/slovakia/education/articles/elisa-technical-guide/>
- Jacob RF. 1994. Multiple-drug-resistant tuberculosis. *Clinical Infectious Diseases*. vol. 19. pp. 1-10.
- Jacobs AJ, Mongkolsapaya J, Sreaton GR, McShane H, Wilkinson RJ. 2016. Antibodies and tuberculosis. *Tuberculosis*. vol. 101. pp. 102-113.

- Jensen EC. 2012. The basics of western blotting. *The Anatomical Record*. vol. 295. pp. 369-371.
- Kaufmann SHE. 2004. New issues in tuberculosis. *Annals of the Rheumatic Diseases*. vol. 63. no. 2. pp. 50-56.
- Kefala G and Weiss MS. 2006. Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of DapA (Rv2753c) from *Mycobacterium tuberculosis*. *Acta Crystallization*. vol. F62. no.11. pp. 1116-1119.
- Kementerian Kesehatan RI Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. 2014. *Pedoman nasional pengendalian tuberkulosis*. Kementerian Kesehatan RI. Jakarta. diakses 26 September 2015. <http://spiritia.or.id/dokumen/pedoman-tbnasional2014.pdf>.
- Kementerian Kesehatan RI (InfoDATIN: Pusat Data dan Informasi Kementerian Kesehatan). 2016. *Tuberkulosis temukan, obati sampai sembuh*. PUSDATIN. Jakarta. diakses 12 Januari 2017. [www.depkes.go.id](http://www.depkes.go.id).
- Kementerian Kesehatan RI. 2017. *Data dan informasi profil kesehatan Indonesia 2016*. Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta. diakses 4 Januari 2018. <http://www.depkes.go.id/resources/download/pusdatin/lain-lain/Data%20dan%20Informasi%20Kesehatan%20Profil%20Kesehatan%20Indonesia%202016%20-%20%20smaller%20size%20-%20web.pdf>.
- Kementerian Kesehatan RI (InfoDATIN: Pusat Data dan Informasi Kementerian Kesehatan). 2018a. *Tuberkulosis*. PUSDATIN. Jakarta. diakses 4 Januari 2019. [www.depkes.go.id](http://www.depkes.go.id)
- Kementerian Kesehatan RI. 2018b. *Data dan informasi profil kesehatan Indonesia 2017*. Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta. diakses 4 November 2018 [http://www.pusdatin.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Data-dan-Informasi\\_Profil-Kesehatan-Indonesia-2017.pdf](http://www.pusdatin.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Data-dan-Informasi_Profil-Kesehatan-Indonesia-2017.pdf)
- Kim EJ, Kim EB, Lee SW, Cheon SA, Kim HJ, Lee J, Lee MK, Ko S, Park TJ. 2017. An easy and sensitive sandwich assay for detection of *Mycobacterium tuberculosis* Ag85B antigen using quantum dots and gold nanorods. *Biosensors and Bioelectronics*. vol. 87. pp. 150-156.
- Kitada S, Maekura R, Toyoshima N, Fujiwara N, Yano I, Ogura T, Ito M, Kobayashi K. 2002. Serodiagnosis of pulmonary disease due to *Mycobacterium avium* complex with an enzyme immunoassay that uses a mixture of glycopeptidolipid antigens. *Clinical Infectious Diseases*. vol. 35. no 11. pp. 1328–1335.



- Kitada S, Maekura R, Toyoshima N, Naka T, Fujiwara N, Kobayashi M, Yano I, Ito M, Kobayashi K. 2005. Use of glycopeptidolipid core antigen for serodiagnosis of *Mycobacterium avium* complex pulmonary disease in immunocompetent patients. *Clinical and Diagnostic Laboratory Immunology*. vol. 12. no. 1. pp. 44-51.
- Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, Takashima T, Nagai T, Sakurabayashi I, Ito M, Maekura R. 2008. Serodiagnosis of *Mycobacterium avium*-complex pulmonary disease using an enzyme immunoassay kit. *American Journal of Respiratory and Critical Care Medicine*. vol. 177. no. 7. pp. 793-797.
- Kitada S, Levin A, Hiserote M, Harbeck RJ, Czaja CA, Huitt G, Kasperbauer SH, Daley CL. 2013. Serodiagnosis of *Mycobacterium avium* complex pulmonary disease in the USA. *European Respiratory Journal*. vol. 42. no. 2. pp. 454-460.
- Kitada S, Maekura R, Yoshimura K, Miki K, Miki M, Oshitani Y, Nishida K, Sawa N, Mori M, Kobayashi K. 2017. Levels of antibody against glycopeptidolipid core as a Marker for monitoring treatment response in *Mycobacterium avium* complex pulmonary disease: a prospective cohort study. *Journal Clinical Microbiology*. vol. 55. no. 3. pp. 884-892.
- Korotkova N, Piton J, Wagner JM, Boy-Röttger S, Aleksandre J, Evans TJ, Cole ST, Pojer F, Korotkov KV. 2015. Structure of EspB, a secreted substrate of the ESX-1 secretion system of *Mycobacterium tuberculosis*. *Journal of Structural Biology*. vol. 191. pp. 236-244.
- Lande L, Alexander DC, Wallace RJ, Kwait RJ, Iakhiaeva E, Williams M, Cameron ADS, Olshefsky S, Devon R, Vasireddy R, Peterson DD, Falkinham JO. 2019. *Mycobacterium avium* in community and household water, suburban Philadelphia, Pennsylvania, USA, 2010 – 2012. *Emerging Infectious Diseases*. vol. 25. no. 3. pp. 473-481.
- Larrea E, Riezu-Boj J-I, Aldabe R, Guembe L, Echeverria I, Balasiddaiah A, Gastaminza P, Civeira MP, Sarobe P, Prieto J. 2014. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. *Gut*. vol. 63. no. 4. pp. 665-673.
- Lee CD, Sun HC, Hu SM, Chiu CF, Homhuan A, Liang SM, Leng CH, Wang TF. 2008. An improved SUMO fusion protein system for effective production of native proteins. *Protein Science*. vol. 17. pp. 1241-1248.
- Lemeshow S, Hosmer DW, Klar J, Lwanga SK. 1990. *Adequacy of sample size in health studies*. John Wiley & Sons Ltd. West Sussex.

- Lin AV. 2015. *Indirect ELISA*. In: Hnasko R. (eds) *ELISA. Methods in molecular biology* vol 1318. Humana Press. New York.
- Liu Y, Zhang X, Zhang Y, Sun Y, Yao C, Wang W, Li C. 2018. Characterization of *Mycobacterium tuberculosis* strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission. *BMC Infectious Diseases*. vol. 18. no. 1. pp. 658.
- López-Varela E, García-Basteiro AL, Augusto OJ, Fraile O, Bulo H, Ira T, Gondo K, van Ingen J, Naniche D, Sacarlal J, Alonso PL. 2017. Correction: high rates of non-tuberculous mycobacteria isolation in Mozambican children with presumptive tuberculosis. *PLoS One*. vol. 12. no. 1. pp. e0175613.
- Lu Y, Xu Y, Yang E, Wang C, Wang H, Shen H. 2012. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and Rv2608 elicits significantly enhanced cellular immune and antibody responses in C57BL/6 Mice. *Basic Immunology*. vol. 76. no. 3. pp. 271-277.
- Lundtoft C, Afum-Adjei Awuah A, Rimpler J, Harling K, Nausch N, Kohns M, Adankwah E, Lang F, Olbrich L, Mayatepek E, Owusu-Dabo E, Jacobsen M. 2017. Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis. *Plos Pathogens*. vol. 13. no. 6. pp. e1006425.
- Lundtoft C, Afum-Adjei Awuah A, Güler A, Harling K, Schaal H, Mayatepek E, Phillips RO, Nausch N, Owusu-Dabo E, Jacobsen M. 2018. An IL7RA exon 5 polymorphism is associated with impaired IL-7R $\alpha$  splicing and protection against tuberculosis in Ghana. *Genes & Immunity*. doi: 10.1038/s41435-018-0049-5.
- Maekura R, Okuda Y, Nakagawa M, Hiraga T, Yokota S, Ito M, Yano I, Kohno H, Wada M, Abe C, Toyoda T, Kishimoto T, Ogira T. 2001. Clinical Evaluation of Anti-Tuberculous Glycolipid Immunoglobulin G Antibody Assay for Rapid Serodiagnosis of Pulmonary Tuberculosis. *Journal of Clinical Microbiolgy*. vol. 39. no. 10. pp. 3603-3608
- Mahboub BH and Vats MG. 2013. *Tuberculosis-current issues in diagnosis and management*, InTech. Croatia. diakses 14 Maret 2016. <http://www.intechopen.com/books/tuberculosis-current-issues-in-diagnosis-and-management>.
- Mahmood T and Yang PC. 2012. Western blot: technique, theory, and trouble shooting. *North American Journal of Medical Science*. vol. 4. no. 9. pp. 429-434.

- Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G. 2015. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. *BMC Infectious Diseases*. vol. 15. pp. 461.
- Mertaniasih NM, Koendhori EB, Kusumaningrum D. 2013a. *Tuberkulosis diagnostik mikrobiologis*. Airlangga University Press (AUP). Surabaya.
- Mertaniasih NM, Wiqoyah N, Kuntaman, Wahyunitisari MR, Kusumaningrum D. 2013b. Polymerase chain reaction of *Mycobacterium tuberculosis* gyrB gene region for rapid screening test of pulmonary tuberculosis. *Folia Medica Indonesiana*. vol. 49. no. 1. pp. 16-20.
- Mertaniasih NM, Kusumaningrum D, Koendhori EB, Soedarsono, Kusmiati T, Dewi DNSS. 2017. Nontuberculous mycobacterial species and *Mycobacterium tuberculosis* complex coinfection in patients with pulmonary tuberculosis in Dr. Soetomo Hospital, Surabaya, Indonesia. *The International Journal of Mycobacteriology*. vol. 6. no. 1. pp. 9-13.
- Miltgen J, Morillon M, Koeck JL, Varnerot A, Briant JF, Nguyen G, Verrot D, Bonnet D, Vincent V. 2002. Two cases of pulmonary tuberculosis caused by *Mycobacterium tuberculosis* subsp. *canetti*. *Emerging Infectious Diseases*. vol. 8. no. 11. pp. 1350-1352.
- Mulisa G, Workneh T, Hordofa N, Suaudi M, Abebe G, Jarso G. 2015. Multidrug-resistant *Mycobacterium tuberculosis* and associated risk factors in Oromia Region of Ethiopia. *International Journal of Infectious Diseases*. vol. 39. pp. 57-61.
- Munshi A. 2012. *DNA sequencing – methods and applications*. InTech. Croatia.
- Nagai S, Wiker HG, Harboe M, Kinomoto M. 1991. Isolation and partial characterization of major protein antigens in the culture fluid of *Mycobacterium tuberculosis*. *Infection and Immunity*. vol. 59. no. 1. pp. 372-382.
- NCBI. 2016. *esxA ESAT-6 protein EsxA [Mycobacterium tuberculosis H37Rv]*. diakses 14 April 2016. <https://www.ncbi.nlm.nih.gov/gene/886209>.
- NIAID. 2007. *Research agenda multidrug resistant and extensively drug-resistant tuberculosis*. NIAID Tuberculosis Working Group. diakses 14 Maret 2016. <http://www.niaid.nih.gov/topics/tuberculosis/research/documents/mdrxdrresearchagenda.pdf>
- Niki M, Suzukawa M, Akashi S, Nagai H, Ohta K, Inoue M, Niki M, Kaneko Y, Morimoto K, Kurashima A, Kitada S, Matsumoto S, Suzuki K, Hoshino Y. 2015. Evaluation of humoral immunity to *Mycobacterium tuberculosis*-specific antigens

- for correlation with clinical status and effective vaccine development. *Journal of Immunology Research*. vol. 2015. ID 527395.
- Nowakowski AB, Wobig WJ, Petering DH. 2014. Native SDS-PAGE: high resolution electrophoretic separation of proteins with retention of native properties including bound metal ions. *Metallomics*. vol. 6. no. 5. pp. 1068-1078.
- Ogbo FA, Ogeleka P, Okoro A, Olusanya BO, Olusanya J, Ifegwu IK, Awosemo AO, Eastwood J, Page A. 2018. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990–2016. *Tropical Medicine and Health*. vol. 46. pp. 34.
- O’Gorman MRG and Donnenberg AD. 2008. *Handbook of Human Immunology 2nd edition*. CRC Press (Taylor & Francis Group). USA.
- Okkels LM and Andersen P. 2004. Protein-protein interactions of proteins from the esat-6 family of *Mycobacterium tuberculosis*. *Society*. vol. 186. no. 8. pp. 2487-2491.
- Osada-Oka M, Tateishi Y, Hirayama Y, Ozeki Y, Niki M, Kitada S, Maekura R, Tsujimura K, Koide Y, Ohara N, Yamamoto T, Kobayashi K, Matsumoto S. 2013. Antigen 85A and mycobacterial DNA-binding protein 1 are targets of immunoglobulin G in individuals with past tuberculosis. *Microbiology Immunology*. vol. 57. pp. 30-37.
- Owen JA, Punt J, Stranford SA. 2007. *Kuby immunology 5th ed*. W. H. Freeman and Company. United States of America.
- Owen JA, Punt J, Stranford SA. 2013. *Kuby immunology 7th ed*. W. H. Freeman and Company. United States of America.
- Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L, Cassone A. 2007. The Ag85B protein of *Mycobacterium tuberculosis* may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th 1 immune response in mice. *Cellular Microbiology*. vol. 9. no. 6. pp. 1455-1465.
- Parija SC. 2012. *Textbook of microbiology & immunology 2nd edition*. Reed Elsevier India Private Limited. New Delhi.
- Pathak SK, Basu S, Basu KK, Banerjee A, Pathak S, Bhattacharyya A, Kaisho T, Kundu M, Basu J. 2007. Direct extracellular interaction between the early secreted antigen ESAT-6 of *Mycobacterium tuberculosis* and TLR2 inhibits TLR signaling in macrophages. *Nature Immunology*. vol. 8. no. 6. pp. 610-618.

- Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Richard S, Vo AA, Ballow M. 2017. Update on the use of immunoglobulin in human disease: A review of evidence. *Journal of Allergy and Clinical Immunology*. vol. 139. no. 3. pp. S1-S46.
- Perumal R, Naidoo K, Padayatchi N. 2018. TB epidemiology: where are the young women? Know your tuberculosis epidemic, know your response. *BMC Public Health*. vol. 18. no. 1. pp. 417
- Playfair JHL and Chain BM. 2012. *At a glance imunologi edisi kesembilan*. Erlangga. Jakarta.
- Prakash R, Kumar D, Gupta VK, Jain S, Chauhan DS, Tiwari PK, Katoch VM. 2016. Status of multidrug resistant tuberculosis (MDR-TB) among the Sahariya tribe of North Central India. *Journal of Infection and Public Health*. vol. 9. no. 3 pp. 289-297.
- Rane L, Rahman S, Magalhaes I, Ahmed R, Spangberg M, Kondova I, Verreck F, Andersson J, Brighenti S, Maeurer MJ. 2011. Increased (6 exon) interleukin-7 production after *M. tuberculosis* infection and soluble interleukin-7 receptor expression in lung tissue. *Genes and Immunity*. vol. 12. pp. 513-522.
- Rashak HA, Sánchez-Pérez HJ, Abdelbary BE, Bencomo-Alerm A, Enriquez-Ríos N, Gómez-Velasco A, Colorado A, Castellanos-Joya M, Rahbar MH, Restrepo BI. 2019. Diabetes, undernutrition, migration and indigenous communities: tuberculosis in Chiapas, Mexico. *Epidemiology and Infection*. vol. 147. pp. e71.
- Roy S and Kumar V. 2012. A Practical approach on SDS PAGE for separation of protein. *International Journal of Science and Research*. vol. 3. no. 8. pp. 955-960.
- Rodríguez-Ezpeleta N, Hackenberg M, Aransay AM. 2012. *Bioinformatics for high throughput sequencing*. Springer Science+Business Media. New York.
- Rogerson BJ, Jung YJ, LaCourse R, Ryan L, Enright N, North RJ. 2006. Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. *Immunology*. vol. 118. no. 2. pp. 195-201.
- Rudolf F, Joaquim LC, Vieira C, Bjerregaard-Andersen M, Andersen A, Erlandsen M, Sodemann M, Andersen PL, Wejse C. 2013. The Bandim tuberculosis score: reliability and comparison with the Karnofsky performance score. *Scandinavian Journal of Infectious Diseases*. vol. 45. pp. 256-264.

- Rudolf F. 2014. The Bandim TBscore - reliability, further development, and evaluation of potential uses. *Global Health Action*. vol. 7. pp. 24303.
- Rudolf F, Wagner AJ, Back FM, Gomes VF, Aaby P, Østergaard L, Eugen-Olsen J, Wejse C. 2017. Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR. *The International Journal of Tuberculosis and Lung Disease*. vol. 21. no. 1. pp. 67-72.
- Sagwa EL, Mantel-Teeuwisse AK, Ruswa NC. 2014. Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study, *Journal of Pharmaceutical Policy and Practice*. vol. 7. no. 1. pp. 14.
- Sambrook J and Russel DW. 2001. *Molecular cloning, a laboratory manual, 3th edition, volume 2*. Cold Spring Harbor Laboratory Press. USA.
- Sanger F. 1981. Sequences in DNA. *Science*. vol. 214. pp. 1205-1210.
- Schluger NW. 2007. Tuberculosis and non-tuberculous mycobacterial infections in older adults. *Clinics in Chest Medicine*. vol. 28. no. 4. pp. 773-781.
- Schorey JS and Sweet L. 2008. The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis. *Glycobiology*. vol. 18. no. 11. pp. 832-842.
- Schroeder HW and Cavacini L. 2010. Structure and function of immunoglobulins. *Journal Allergy Clinical Immunology*. vol. 125. no. 2. pp. 41-52.
- Schuller M, Sloots TP, James GS, Halliday CL, Carter IWJ. 2010. *PCR for clinical microbiology an australian and international perspective*. Springer Science+Business Media. New York.
- Sharma SK and Mohan A. 2004. Multidrug-resistant tuberculosis. *Indian Journal Medical Research*. vol. 120. pp. 354-376.
- Silva VMC, Kanaujia G, Gennaro ML, Menzies D. 2003. Factors associated with humoral response to ESAT-6, 38 kDa and 14 kDa in patients with a spectrum of tuberculosis. *International Journal of Tuberculosis and Lung Disease*. vol. 7. no. 5. pp. 478-484.
- Simeone R, Bottai D, Frigui W, Majlessi L, Brosch R. 2015. ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection. *Tuberculosis*. vol. 95. pp. 150-154.

- Simonney B, Chavanet P, Perronne C, Leportier M, Revol F, Herrmann JL, Lagrange PH. 2007. B-cell immune responses in HIV positive and HIV negative patients with tuberculosis evaluated with an ELISA using a glycolipid antigen. *Tuberculosis*. vol. 87. pp. 109-112.
- Singh S, Gopinath K, Shahdad S, Kaur M, Singh B, Sharma P. 2007. Nontuberculous *mycobacterial* infection in Indian AIDS patients detected by a novel set of ESAT-6 polymerase chain reaction primers. *Japanese Journal of Infectious Disease*. vol. 60. no. 1. pp.14-18.
- Singleton P. 2000. *DNA methods in clinical microbiology*. Springer Science+Business Media. Dordrecht.
- Soedarsono. 2015. Asosiasi polimorfisme gen TLRs dengan derajat keparahan penyakit pasien tb paru mdr dan peran sekuens gen *esxA*. *Disertasi*. Program Studi Ilmu Kedokteran Jenjang Doktor. Fakultas Kedokteran Universitas Airlangga.
- Soedarto. 2015. *Mikrobiologi Kedokteran*. Sagung Seto. Jakarta.
- Solans L, Aguiló N, Samper S, Pawlik A, Frigui W, Martín C, Brosch R, Gonzalo-Asensio J. 2014. A specific polymorphism in *Mycobacterium tuberculosis* H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component. *Journal of Infection and Immunity*. vol. 82. no. 8. pp. 3446-3456.
- Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, Ramsay A, Pai M, Laal S. 2009. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. *Clinical and Vaccine Immunology*. vol. 16. no. 2. pp. 260-276.
- Stevenson CR, Crithchley JA, Forouhi NG, Roglic G, Williams BG, Dye C, Unwin NC. 2007. Diabetes and the risk of tuberculosis: a neglected threat to public health?. *Chronic Illness*. vol. 3. no. 3. pp. 228-245.
- Sudre P, Dam GT, Kochi A. 1992. Tuberculosis: a global overview of the situation today. *Bulletin of The World Health Organization*. vol. 70. no. 2. pp. 149-159.
- Surkova L, Horevich HL, Titov LP, Sahalchyk E, Arjomandzadegan M, Alinejad S, Sadrnia M. 2012. A study on demographic characteristics of drug resistant *Mycobacterium tuberculosis* isolates in Belarus. *International Journal of Mycobacteriology*. vol. I. no. 2. pp. 75-81.
- Takei F and Nakatani K. 2013. The chemistry of pcr primers: concept and application. *Israel Journal of Chemistry*. vol. 53. pp. 1-16.

- Tan Y, Su B, Shu W, Cai X, Kuang S, Kuang H, Liu J, Pang Y. 2018. Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013–2016. *BMC Pulmonary Medicine*. vol. 18. pp. 168.
- Taniguchi K, Takii T, Yamamoto S, Maeyama JI, Iho S, Maruyama M, Iizuka N, Ozeki Y, Matsumoto S, Hasegawa T, Miyatake Y, Itoh S, Onozaki K. 2013. Reactivation of immune responses against *Mycobacterium tuberculosis* by boosting with the CpG oligomer in aged mice primarily vaccinated with *Mycobacterium bovis* BCG. *Immunity & Ageing*. vol. 10. pp. 25.
- Tape TG. 2000. *Using the receiver operating characteristic (ROC) curve to analyze a classification model*. University of Nebraska Medical Center. diakses 19 Oktober 2018. <http://gim.unmc.edu/dxtests/effect1.htm>.
- Tasbiti AH, Yari S, Ghanei M, Shokrgozar MA, Fateh A, Bahrmand A. 2017. Low level of extensively drug-resistant tuberculosis among MDR-TB isolates and its relationship to risk factors: surveillance in Tehran-Iran. *Osong Public Health Research Perspective*. vol. 8. no. 2. pp. 116-123.
- TB Database. 2010. *Rv3875-6 kda early secretory antigenic target esxA*. diakses 14 April 2016. <http://genome.tdb.org/cgi-bin/GeneDetails.html?id=SRv3875>.
- Tegegne BS, Habtewold TD, Mengesha MM, Burgerhof GM. 2017. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. *Systematic Reviews*. vol. 2017. no. 6. pp. 1-5.
- Terrazzini N, Mantegani P, Kern F, Fortis C, Mondino A, Caserta S. 2018. Interleukin-7 unveils pathogen-specific T Cells by enhancing antigen-recall responses. *Journal of Infectious Diseases*. vol. 217. no 12. pp. 1997-2007.
- Teutschbein J, Schumann G, Möllmann U, Grabley S, Cole ST, Munder T. 2009. A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of *Mycobacterium tuberculosis*. *Microbiological Research*. vol. 164. pp. 253-259.
- Thang PH, Ruffin N, Brodin D, Rethi B, Cam PD, Hien NT, Lopalco L, Vivar N, Chiodi F. 2010. The role of IL-1 $\beta$  in reduced IL-7 production by stromal and epithelial cells: a model for impaired T-cell numbers in the gut during HIV-1 infection. *Journal of Internal Medicine*. vol. 268. no. 2. pp. 181-193.
- Tille PM. 2014. *Bailey & scott's diagnostic microbiology 13<sup>th</sup> edition*. Elsevier Mosby. Missouri.
- Tipu HN and Shabbir A. 2015. Evolution of DNA sequencing. *Journal of the College of Physicians and Surgeons Pakistan*. vol. 25. no. 3. pp. 210-215.



- Todar K. 2012 *Mycobacterium tuberculosis and tuberculosis*. diakses 25 Maret 2016. <http://textbookofbacteriology.net/tuberculosis.html>
- Tuberculist. 2013. *fbpB*. diakses 28 Maret 2018. <http://svitsrv8.epfl.ch/tuberculist/quicksearch.php?gene+name=fbpB&submit=Search>
- Tullius MV, Harth G, Masleša-Galić S, Dillon BJ, Horwitz MA. A replication-limited recombinant *Mycobacterium bovis* BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. *Infection and Immunity*. vol. 76, no. 11. pp. 5200-5214.
- Turner RD and Bothamley GH. 2015. Cough and the transmission of tuberculosis. *The Journal of Infectious Diseases*. vol. 211. no. 9. pp. 1367-1372.
- Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, Cioboata R, Llontop JC, Kleynhans L, Lopez S, Santoso P, Marius C, Villaizan K, Ruslami R, Walzl G, Panduru NM, Dockrell HM, Hill PC, McAllister S, Pearson F, Moore DAJ, Critchley JA, van Crevel R. 2019. Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study. *Clinical Infectious Diseases*. ciz284. doi: 10.1093/cid/ciz284.
- Uplekar S, Heym B, Friocourt V, Rougemont J, Cole ST. 2011. Comparative genomics of *esx* genes from clinical isolates of *Mycobacterium tuberculosis* provides evidence for gene conversion and epitope variation. *Journal Infection and Immunity*. vol. 79. no. 10. pp. 4042-4049.
- van Crevel R, Ottenhoff THM and van der Meer JWM. 2002. Innate immunity to *Mycobacterium tuberculosis*. *Clinical Microbiology Reviews*. vol. 15. no. 2. pp. 294-309.
- Virenfeldt J, Rudolf F, Camara C, Furtado A, Gomes V, Aaby P, Petersen E, Wejse C, 2014. Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. *BMJ Open*. vol. 4. pp. e004818.
- Wakabayashi K. 2010. *ELISA- A to Z from introduction to practice*. Shibayagi Co Ltd. Jepang.
- Walker JM. 2002. *Protein protocols handbook second edition*. Humana Press Inc. United States of America.

- Weber K and Osborn M. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *The Journal of Biological Chemistry*. vol. 244. no. 16. pp. 4406-4412.
- WHO. 2010. *Multidrug and extensively drug-resistant tb (m/xdr-tb) 2010 global report on surveillance and response*. World Health Organization. Geneva. diakses tanggal 14 Maret 2016. [http://apps.who.int/iris/bitstream/10665/44286/1/9789241599191\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44286/1/9789241599191_eng.pdf).
- WHO. 2014. *Global tuberculosis report 2014*. World Health Organization. Geneva. diakses 14 Januari 2016. <http://www.who.int/tb/country/en/>.
- WHO. 2015a. *Implementation tuberculosis diagnostics*. World Health Organization. Geneva. diakses 17 Juni 2016. [http://apps.who.int/iris/bitstream/10665/162712/1/9789241508612\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/162712/1/9789241508612_eng.pdf)
- WHO. 2015b. *Tuberculosis control in the South-East Asia region*. World Health Organization. Geneva. diakses 1 Desember 2015. <http://www.searo.who.int/tb/annual-tb-report-2015.pdf>.
- WHO. 2015c. *Global tuberculosis report 2015*. World Health Organization. Geneva. diakses 1 Desember 2015. [http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1).
- WHO. 2016a. *Global tuberculosis report 2016*. World Health Organization. Geneva. diakses 12 Januari 2017. <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1>
- WHO. 2016b. *Tuberculosis control in the South-East Asia Region*. World Health Organization. Geneva. diakses 4 Januari 2018. <http://apps.who.int/iris/handle/10665/205286>
- WHO. 2016c. *WHO treatment guidelines for drug-resistant tuberculosis*. World Health Organization. Geneva. diakses 26 September 2016. <http://www.who.int/tb/MDRTBguidelines2016.pdf>.
- WHO. 2017. *Global tuberculosis report 2017*. World Health Organization. Geneva. diakses 7 Desember 2017. <http://apps.who.int/iris/bitstream/10665/259366/1/9789241565516-eng.pdf?ua=1>
- WHO. 2018. *Global tuberculosis report 2018*. World Health Organization. Geneva. diakses 30 September 2018. <https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1>

- Yang H, Kruh-Garcia NA, Dobos KM. 2012. Purified Protein Derivatives of Tuberculin - Past, Present, and Future. *Medical Microbiology and Immunology*. vol. 66. no. 3. pp. 273-280.
- You E, Kim M, Lee WI, Kang SY. 2016. Evaluation of IL-2, IL-10, IL-17 and IP-10 as potent discriminative markers for active tuberculosis among pulmonary tuberculosis suspects. *Tuberculosis*. vol. 99. pp. 100-108.
- Yu X and Xie J. 2012. Roles and underlying mechanisms of ESAT-6 in the context of *Mycobacterium tuberculosis*-host interaction from a systems biology perspective. *Cellular Signalling*. vol. 24. pp. 1841-1846.
- Zhang W, Shu Q, Zhao Z, Fan J, Lyon CJ, Zelazny AM, Hu Y. 2018. Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. *Clinical Proteomics*. vol. 15. pp. 1.
- Zhang CY, Zhao F, Xia YY, Yu YL, Shen X, Lu W, Wang XM, Xing J, Ye JJ, Li JW, Liu FY, Wu JL, Xu L, Zhang H, Cheng J, Wang LX. 2019. Prevalence and risk factors of active pulmonary tuberculosis among elderly people in China: a population based cross-sectional study. *Infectious Diseases of Poverty*. vol. 8. no.1. pp. 7.
- Zhao J, Shiratori B, Okumura M, Yanai H, Matsumoto M, Nakajima C, Mizuno K, Ono K, Oda T, Chagan-Yasutan H, Ashino Y, Matsuba T, Yoshiyama T, Suzuki Y, Hattori T. 2017a. Difference in antibody responses to *mycobacterium tuberculosis* antigens in japanese tuberculosis patients infected with the beijing/non-beijing genotype. *Journal of Immunology Research*. vol. 2017. pp. 4797856.
- Zhao J, Matsuba T, Zhang X, Leano S, Nakajima C, Chagan-Yasutan H, Telan EF, Suzuki Y, Hattori T. 2017b. Comparison of antibody responses against *Mycobacterium tuberculosis* antigen Rv0679c in tuberculosis patients from the endemic and non-endemic regions of the Beijing genotype: a case control study. *BMC Infectious Diseases*. vol. 14. pp. 344.